Psilocybin for Methamphetamine Addiction
Open-label, single-arm early Phase I pilot (n=20) assessing feasibility and tolerability of a single 25 mg oral psilocybin dose to promote abstinence in adults receiving residential treatment for methamphetamine dependence.
Details
Open-label pilot enrolling 20 participants receiving residential treatment for methamphetamine dependence to evaluate feasibility, tolerability, and preliminary signals of effectiveness following a single 25 mg oral psilocybin dose.
Participants complete baseline assessments, three preparatory sessions (two may be remote), a single monitored psilocybin session (6–8 hours), two post-session telehealth integration visits, and follow-up assessments to 120 days including urine drug screens.
Outcomes include retention and safety (feasibility/tolerability), methamphetamine abstinence, craving, negative affect, cognitive function, quality of life, and measures of the acute and persisting psilocybin experience.